News & Events about Mink Therapeutics Inc.
Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.In a patient with metastatic gastric cancer who had no response to treatment with pembrolizumab and nivolumab/FOLFOX, agenT-797 induced a partial ...
Ticker Report
2 months ago
MiNK Therapeutics (NASDAQ:INKT Get Rating) had its price target reduced by stock analysts at Evercore ISI from $4.00 to $3.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The firm presently has an outperform rating on the stock. Evercore ...
Globe Newswire
2 months ago
Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023Allogeneic CAR platform demonstrates differentiation with IL-15-FAP-CAR-iNKT (MiNK-215) and IL-15-...
Globe Newswire
2 months ago
Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and ...
Globe Newswire
3 months ago
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune...